Neurofilaments

The C-Reactive Protein of Neurology

Lambertsen, Kate Lykke; Soares, Catarina B.; Gaist, David; Nielsen, Helle Hvilsted

Published in:
Brain Sciences

DOI:
10.3390/brainsci10010056

Publication date:
2020

Document version
Final published version

Document license
CC BY

Citation for published version (APA):
Lambertsen, K. L., Soares, C. B., Gaist, D., & Nielsen, H. H. (2020). Neurofilaments: The C-Reactive Protein of Neurology. Brain Sciences, 10(1), [56]. https://doi.org/10.3390/brainsci10010056

Terms of use
This work is brought to you by the University of Southern Denmark through the SDU Research Portal. Unless otherwise specified it has been shared according to the terms for self-archiving. If no other license is stated, these terms apply:

- You may download this work for personal use only.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying this open access version

If you believe that this document breaches copyright please contact us providing details and we will investigate your claim. Please direct all enquiries to puresupport@bib.sdu.dk
Neurofilaments: The C-Reactive Protein of Neurology

Kate L. Lambertsen 1,2,3, Catarina B. Soares 1,2, David Gaist 1,3,4 and Helle H. Nielsen 1,2,3,4,*

1 Department of Neurology, Odense University Hospital, J.B. Winsloewsvej 4, 5000 Odense C, Denmark; klambertsen@health.sdu.dk (K.L.L.); catarinamsoares@hotmail.com (C.B.S.); david.gaist@rsyd.dk (D.G.)
2 Department of Neurobiology Research, Institute of Molecular Medicine, University of Southern Denmark, J.B. Winsloewsvej 21, st, 5000 Odense C, Denmark
3 BRIDGE—Brain Research—Inter Disciplinary Guided Excellence, Department of Clinical Research, University of Southern Denmark, J.B. Winsloewsvej 19, 3. sal, 5000 Odense C, Denmark
4 Department of Clinical Research, Neurology Research Unit, Faculty of Health Sciences, University of Southern Denmark, Campusvej 55, 5230 Odense, Denmark
* Correspondence: hhnielsen@health.sdu.dk

Received: 21 December 2019; Accepted: 16 January 2020; Published: 18 January 2020

Abstract: Neurofilaments (NFs) are quickly becoming the biomarkers of choice in the field of neurology, suggesting their use as an unspecific screening marker, much like the use of elevated plasma C-reactive protein (CRP) in other fields. With sensitive techniques being readily available, evidence is growing regarding the diagnostic and prognostic value of NFs in many neurological disorders. Here, we review the latest literature on the structure and function of NFs and report the strengths and pitfalls of NFs as markers of neurodegeneration in the context of neurological diseases of the central and peripheral nervous systems.

Keywords: neuroaxonal damage; biomarker; blood; serum; plasma

1. Introduction

The interest in neurofilaments (NFs) and their role as disease biomarkers has grown immensely in recent years. NFs were first tested as possible biomarkers by Rosengren et al., who detected an increase in cerebrospinal fluid (CSF) NF-light chain (NF-L) in patients with Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS) compared to controls [1]. This study sparked the interest in NFs as biomarkers, especially the NF-L subunit, not only in neurodegenerative diseases but also in inflammatory, vascular, and traumatic diseases of the central nervous system (CNS) and recently in the peripheral neuropathies (Table 1). Since NFs are solely located in the neuronal cytoskeleton and are released to the interstitial fluid in high quantities upon axonal injury and/or neurodegeneration, they are highly specific for neuronal damage and death [2]. From the interstitial fluid, NFs move to the CSF and subsequently to the blood, where their levels can be measured in serum and plasma and correlated to the extent of axonal damage or neurodegeneration (Figure 1 and Table 1). In recent years, CSF has been the main source for NF analysis, but this is obtained infrequently and only in clinically relevant pathologies due to the invasive nature of lumbar punctures. This has meant that most studies using NF as a marker were restricted to a small spectrum of CNS diseases and disregarded the axonal pathologies of the peripheral nervous system (PNS), not only because of limitations in obtaining relevant biological material like CSF but also because of the quantification methods available. Techniques like ELISA and electrochemiluminescence (ECL) assays can detect NF in peripheral blood, but their sensitivity does not allow very reliable measurements or identification of small variations in concentrations. Single molecule array technology (Simoa™) was introduced in 2010 [3], however, and its higher sensitivity has greatly helped in establishing NF-L as a biomarker in CSF, serum, and plasma [4,5]. Here, we review fundamental developments in the assessment of NFs as biomarkers in
human studies and the contribution of NFs to disease monitoring and effectiveness of current and developing therapies.

**Figure 1.** Neurofilament after neuroaxonal damage. (a) Immunohistochemical staining of neurofilament-positive neurons in post-mortem human ischemic cerebellum tissue. Scale bar: 100 µm. (b) High magnification of squared area in (a) showing neurofilament-positive neurons. Scale bar: 40 µm. Neurofilament immunohistochemical staining was performed on parallel tissue sections from post-mortem ischemic brain tissue used in previous studies [6–9]. Staining was performed using similar protocols and the following antibody: monoclonal mouse anti-neurofilament (phosphorylated and non-phosphorylated NF-H chain) antibody (clone N52, 1:1000, Sigma-Aldrich, St. Louis, MO, USA). The use of human brains was approved by the Danish Biomedical Research Ethical Committee for the Region of Southern Denmark (permission number S-20080042). (c) Schematic presentation of neuroaxonal damage leading to neurofilament release. When a neuron and its axon are damaged, neurofilament is released into the extracellular space (A) and subsequently into the cerebrospinal fluid (CSF) and blood (B), where it can be detected in increased levels following neuroaxonal damage. Abbreviations: BBB, blood–brain barrier; NF, neurofilament.
Table 1. Overview of neurofilaments as biomarkers of neurological disease. Abbreviations used in table: AD, Alzheimer’s disease; ADAD, autosomal dominant Alzheimer’s disease; AIS, acute ischemic stroke; ALS, amyotrophic lateral sclerosis; aMCI, amnestic mild cognitive impairment; aSAH, aneurysmal subarachnoid hemorrhage; CA, cardiac arrest; CADASIL, cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy; CBS, corticobasal syndrome; CeAD, cervical artery dissection; CIDP, chronic inflammatory demyelinating polyneuropathy; CMT, Charcot–Marie–Tooth; CSF, cerebrospinal fluid; ECL, electrochemiluminescence; FTD, frontotemporal dementia; GBS, Guillain–Barré syndrome; GCS, Glasgow Coma Scale; HD, Huntington’s disease; HHT, hereditary hemorrhagic telangiectasia; HS, hemorrhagic stroke; MCI, mild cognitive impairment; MMN, multifocal motor neuropathy; MND, motor neuron disease; MS, multiple sclerosis; MSA, multiple system atrophy; NF-M, neurofilament medium chain; ON, optic neuritis; PD, Parkinson’s disease; pNF-L, plasma neurofilament light chain; p-pNF-H, plasma phosphorylated neurofilament heavy chain; PSP, progressive supranuclear palsy; ROSC, return of spontaneous circulation; RSSI, recent small subcortical infarcts; SAH, subarachnoid hemorrhage; SCI, spinal cord injury; s-pNF-H, serum-phosphorylated neurofilament heavy chain; Simoa, single molecule array; sNF-L, serum neurofilament light chain; SVD, small vessel disease; TIA, transient ischemic attack; WMH, white matter hyperintensities; WML, white matter lesions.

| Disease and Sample Size | Protein | Method | Time Profile, Association with Disease Activity, and Diagnostic and/or Prognostic Relevance | Reference |
|-------------------------|---------|--------|---------------------------------------------------------------------------------|-----------|
| **Neuropathies**        |         |        |                                                                                  |           |
| • 20 GBS patients and 67 controls | CSF NF-L and sNF-L | ECL | Elevated sNF-L and CSF NF-L in GBS patients compared to controls | [2]       |
| • GBS (5), MMN (3), CIDP (12); AntiMAG (3), CIDP + antiMAG (1) vasculitic neuropathy (1) and 25 controls | CSF NF-L; pNF-L | Simoa | Elevated pNF-L and CSF NF-L in GBS, CIDP and antiMAG vs. controls | [10]      |
| • 30 vasculitic neuropathy patients and 30 controls | sNF-L | Simoa | Elevated sNF-L during active disease vs. controls | [11]      |
| • 18 GBS and 18 controls | CSF NF-L | ELISA | Elevated CSF NF-L in GBS vs. controls, correlation with severity and outcome | [12]      |
| • 75 CMT and 67 controls | pNF-L | Simoa | Elevated pNF-L vs. control correlated with severity | [13]      |
| **Amyotrophic Lateral Sclerosis** |         |        |                                                                                  |           |
| • 67 controls and 20 ALS patients | CSF NF-L, sNF-L | ECL | Elevated sNF-L and CSF NF-L in ALS vs. controls | [2]       |
| • 103 patients and 42 controls | CSF NF-L, sNF-L, pNF-L | ECL | Blood-derived NF-L level is an easily accessible biomarker with prognostic value in ALS | [14]      |
Table 1. Cont.

| Disease and Sample Size                                                                 | Protein | Method | Time Profile, Association with Disease Activity, and Diagnostic and/or Prognostic Relevance                                                                 | Reference |
|----------------------------------------------------------------------------------------|---------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| • 124 ALS, 44 ALS mimics, 65 other neurodegenerative disorders, and 50 healthy controls | sNF-L   | Simoa  | Serum NF-L is elevated in ALS and can distinguish between ALS mimics and correlate with prognosis                                                                                              | [15]      |
| • 12 asymptomatic carriers, 64 symptomatic carriers, and 19 healthy family controls     | CSF NF-L, sNF-L | Simoa  | Symptomatic carriers have higher levels of NFs in serum and CSF compared to controls, blood NF-L increases 12 months before symptom onset                                                       | [16]      |
| • 715 MND, 87 FTD, and 107 controls                                                   | CSF NF-L | Simoa  | High levels of NF-L associated with shorter survival                                                                                                                                       | [17]      |
| Multiple Sclerosis                                                                      |         |        |                                                                                                                          |           |
| • 56 ON patients and 27 controls enrolled within 28 days of onset (median 16 days)      | CSF NF-L | ELISA  | No correlation between NF-L and MS-risk parameters                                                                                                                                  | [18]      |
| • 47 ON patients enrolled within 28 days of onset (median 16 days)                     | CSF NF-L | ELISA  | CSF NF-L predicted visual outcome after ON                                                                                                                                       | [19]      |
| • 68 ON patients                                                                       | CSF NF-L | ELISA  | CSF NF-L predicted long-term physical and cognitive disability                                                                                                                         | [20]      |
| • 589 patients and 33 controls                                                        | pNF-L   | Simoa  | pNF-L levels associated with disease activity and have prognostic value                                                                                                                  | [21]      |
| • 74 patients                                                                         | sNF-L   | Simoa  | sNF-L correlated with MRI activity                                                                                                                                             | [22]      |
| • 122 patients                                                                        | sNF-L   | Simoa  | sNF-L predicted 10 year lesion load and atrophy                                                                                                                                | [23]      |
| • 189 RRMS and 70 PMS                                                                  | sNF-L   | Simoa  | sNF-L correlated with concurrent and future clinical and MRI measures of disease activity and severity                                                                          | [24]      |
Table 1. Cont.

| Disease and Sample Size | Protein | Method | Time Profile, Association with Disease Activity, and Diagnostic and/or Prognostic Relevance | Reference |
|-------------------------|---------|--------|-------------------------------------------------------------------------------------------------|-----------|
| Alzheimer’s Disease     |         |        |                                                                                                |           |
| • 67 controls and 20 AD patients | CSF NF-L, sNF-L | ECL | Elevated sNF-L and CSF NF-L in AD patients compared to controls                                 | [2]       |
| • 42 ADAD patients (22 symptomatic and 20 asymptomatic mutation carriers) and 18 controls | CSF NF-L, sNF-L | Simoa | sNF-L correlated with clinical and cognitive measures in ADAD and with CSF NF-L. Elevated sNF-L in symptomatic vs. asymptomatic carriers and controls | [25]      |
| • 243 ADAD mutation carriers and 162 controls | CSF NF-L, sNF-L | Simoa | Elevated sNF-L and CSF NF-L levels in ADAD compared to controls. sNF-L predicted disease progression and neurodegeneration at the early pre-symptomatic stages | [26]      |
| • 198 aMCI and 187 AD patients, and 193 controls | pNF-L | Simoa | Elevated pNF-L in aMCI and AD patients compared to controls and elevated in AD compared to aMCI. pNF-L associated with cognition | [27]      |
| • 99 MCI and 33 early AD patients, and 41 controls | pNF-L | Simoa | Elevated pNF-L in MCI and early AD patients compared to controls                                | [28]      |
| • Down syndrome-associated AD (194 asymptomatic, 39 prodromal, and 49 symptomatic), and 67 controls | CSF NF-L, pNF-L | ELISA | Elevated NF-L in prodromal and symptomatic AD compared to controls. pNF-L and CSF NF-L differentiated between asymptomatic, prodromal, and symptomatic AD. CSF NF-L and pNF-L correlated. | [29]      |
| • 197 MCI and 180 AD patients, and 193 controls | pNF-L | Simoa | Elevated pNF-L in MCI and AD patients compared to controls. CSF NF-L and pNF-L correlated. pNF-L associated with poor cognition, AD-related atrophy, and brain hypometabolism | [30]      |
| • 56 MCI and 119 AD patients, and 59 controls | pNF-L | Simoa | Elevated pNF-L in AD compared to controls. pNF-L associated with cognition                        | [31]      |
### Table 1. Cont.

| Disease and Sample Size | Protein | Method | Time Profile, Association with Disease Activity, and Diagnostic and/or Prognostic Relevance | Reference |
|-------------------------|---------|--------|------------------------------------------------------------------------------------------|-----------|
| **Huntington’s Disease** |         |        |                                                                                          |           |
| • 11 premanifest and 12 manifest HD patients | CSF NF-L | ELISA | CSF NF-L correlated with 5 year probability of disease onset, functional capacity, and total motor score | [32]      |
| • 20 premanifest, 40 manifest HD patients, and 20 controls | CSF NF-L and pNF-L | ELISA | CSF and pNF-L were increased in premanifest and manifest HD patients vs. controls. Manifest HD displayed higher levels vs. premanifest HD patients | [33]      |
| • 29 early, 29 premanifest, and 30 moderate HD patients, and 29 controls | pNF-H | ELISA | No correlation between pNF-H and disease stage | [34]      |
| • 201 individuals carrying HHT mutations and 97 controls | pNF-L | Simoa | pNF-L correlated with clinical and MRI findings | [35]      |
| • 35 HD patients and 35 controls | CSF NF-L | ELISA | Elevated CSF NF-L in HD patients vs. controls. CSF NF-L correlated to functional capacity | [36]      |
| • 32 premanifest, 48 manifest HD patients, and 24 controls | CSF NF-L | ELISA | Elevated CSF NF-L in premanifest and manifest HD compared to controls, and increased levels in manifest compared to premanifest HD patients | [37]      |
| **Parkinson’s Disease and Parkinsonian Disorders** |         |        |                                                                                          |           |
| • Cohort 1: 171 PD, 30 MSA, 19 PSP, five CBS, and 53 healthy controls. | sNF-L and pNF-L | Simoa | Elevated sNF-L and pNF-L in MSA, PSP, and CBS vs. PD and healthy controls. sNF-L and pNF-L discerned between PD and MSA, PSP, and CBS | [38]      |
| • Cohort 2: 20 PD, 30 MSA, 29 PSP, 12 CBS, and 26 healthy controls | sNF-L and pNF-L | Simoa |                                                                                          |           |
**Table 1. Cont.**

| Disease and Sample Size | Protein | Method | Time Profile, Association with Disease Activity, and Diagnostic and/or Prognostic Relevance | Reference |
|-------------------------|---------|--------|-------------------------------------------------------------------------------------------|-----------|
| • 26 non-demented PD and 23 demented PD patients, and 59 controls | pNF-L | Simoa | Elevated pNF-L in demented vs. non-demented and controls. pNF-L associated with cognition | [31] |
| • 64 non-demented PD patients and 21 controls | CSF NF-L | ELISA | CSF NF-L levels increased in PD patients over 2 years, but not in controls | [39] |
| • 68 PD, 34 MSA, 34 PSP, and 15 CBS | CSF NF-L | ELISA | CSF NF-L associated with increased mortality | [40] |

**Stroke—AIS, TIA and HS**

| Disease and Sample Size | Protein | Method | Time Profile, Association with Disease Activity, and Diagnostic and/or Prognostic Relevance | Reference |
|-------------------------|---------|--------|-------------------------------------------------------------------------------------------|-----------|
| • 595 AIS enrolled within 14 days after symptom onset and 600 controls | sNF-L | Simoa | sNF-L levels highest 3 months post-stroke. sNF-L associated with stroke severity and poor outcomes. sNF-L levels higher compared to controls. | [41] |
| • 101 AIS and 35 TIA patients enrolled within 1–12 days (63.8 ± 50.1 h) | sNF-L | Simoa | Elevated sNF-L in AIS compared to TIA. sNF-L correlated with final infarct volume. | [42] |
| • 44 controls and 54 AIS on day 1, week 1, and 3–6 weeks post-stroke | s-pNF-H | ELISA | Elevated s-pNF-H in AIS vs. controls. s-pNF-H at week 3 correlated to stroke severity, size, and outcome | [43] |
| • 30 controls and 196 AIS patients on admission, days 2, 3, and 7, as well as 3 and 6 weeks post-stroke | sNF-L | Simoa | Elevated sNF-L at admission until 6 months in AIS compared to controls. sNF-L correlated with infarct volume at day 7 | [44] |
| • 504 AIS and 111 TIA patients within 24 h of symptom onset | sNF-L | ECL | Elevated sNF-L in AIS vs. TIA. sNF-L associated with NIHSS and TIA diagnosis but not infarct size or functional outcome at 3 months | [45] |
| • 20 controls and 20 AIS enrolled within 5–10 days | CSF NF-L | ELISA | Elevated NF-L in AIS compared to controls. NF-L correlated with the degree of WML | [46] |
| Disease and Sample Size | Protein | Method | Time Profile, Association with Disease Activity, and Diagnostic and/or Prognostic Relevance | Reference |
|-------------------------|---------|--------|----------------------------------------------------------------------------------------|-----------|
| • 49 CeAD patients (10 TIA, 31 AIS, eight local symptoms) within 30 days of symptom onset | sNF-L | ECL | Elevated sNF-L in CeAD stroke vs. CeAD TIA. SNF-L associated with NIHSS. Elevated sNF-H levels within 24 h post-stroke | [47] |
| • 22 AIS patients enrolled within 6–24 h after symptom onset | sNF-H | ELISA | Elevated sNF-L levels in RSSI at baseline and 3 months vs. controls. sNF-L associated with RSSI size and baseline WMH severity | [48] |
| • 79 RSSI at baseline, 3 and 15 months post-stroke and 53 community-dwelling healthy controls with comparable WMH | sNF-L | Simoa | NF-M levels higher in HS vs. AIS and controls | [49] |
| • 10 controls, 11 AIS, and 30 HS within 1 day (TIA) and 5 days (HS) | CSF NF-M | ELISA | NF-H correlated with functional outcome at discharge | [50] |
| • 20 controls and 33 AIS patients within 3 days of symptom onset | CSF NF-H and sNF-L | ELISA | No difference between AIS and controls | [51] |
| **Stroke—Small Vessel Disease** | **Stroke—SAH** | **Stroke—SAH** | **Stroke—SAH** | **Stroke—SAH** |
| • 53 SVD patients | CSF NF-L | ELISA | CSF NF-L associated with volume of WMLs | [52] |
| • 93 controls, 53 CADASIL, and 439 SVD patients | sNF-L | Simoa | Elevated sNF-L in CADASIL and SVD patients compared to controls. sNF-L levels associated with imaging and clinical features of SVD | [53] |
| • 35 aSAH patients serially for up to 15 days | CSF NF-L | ELISA | Elevated CSF NF-L levels. No effect on secondary adverse events or long-term outcome | [54] |
| Disease and Sample Size | Protein               | Method | Time Profile, Association with Disease Activity, and Diagnostic and/or Prognostic Relevance | Reference |
|-------------------------|-----------------------|--------|------------------------------------------------------------------------------------------|-----------|
| 40 patients with Fisher grade 3 hemorrhage within 6 hrs each day for up to 8–12 days | CSF pNF-H, s-pNF-H | ELISA  | pNF-H levels differentiated between patients with poor and favorable outcomes | [55]      |
| Severe Traumatic Brain Injury |                       |        |                                                                                          |           |
| 172 neurocritical TBI at bout and at 12 months | sNF-L | Simoa | sNF-L increased over 2 weeks, predicted 12 months outcome | [56]      |
| 182 TBI, outcome 6–12 months | CSF NF-L, sNF-L | ELISA  | Higher NF-L CSF and serum levels correlated to GCS and predicted a poor clinical outcome | [57]      |
| 72 TBI and 35 controls | sNF-L | Simoa | High initial NF-L levels predicted poor clinical outcome at 1 year | [58]      |
| Mild Traumatic Injury |                       |        |                                                                                          |           |
| 107 mild traumatic brain injury | pNF-L | Simoa | Early levels of NF-L predicted outcome 6–12 months | [59]      |
| 118 elderly mild traumatic injury +/- neurological disorders + 40 age-matched controls | sNF-L | Simoa | Older age and neurological diseases are associated with elevated serum NF-L levels in TBI and controls | [60]      |
| Sport—Related Concussion |                       |        |                                                                                          |           |
| 142 American football + hockey players with concussion: preseason, day 6 and 14 | sNF-L | Simoa | No difference in sNF-L with uncomplicated concussion | [61]      |
| 45 boxers and 25 controls | sNF-L, CSF NF-L | ELISA  | Higher NF-L CSF and serum levels correlated to GCS and predicted a poor clinical outcome. Elevated CSF NF-L after bout and after 14 days | [62]      |
Table 1. Cont.

| Disease and Sample Size | Protein | Method | Time Profile, Association with Disease Activity, and Diagnostic and/or Prognostic Relevance | Reference |
|-------------------------|---------|--------|------------------------------------------------------------------------------------------|-----------|
| • Experimental soccer headings vs. sham vs. control | pNF-L | ELISA | Elevated p NF-L at 1 h and 1 month | [61] |
| • 19 American football players, 19 swimmers, eight samples over 6 months | sNF-L | Simoa | Increased sNF-L over time in football players | [63] |
| • 18 football players, accelerometer-embedded mouthguard | pNF-L | Simoa | The frequency and magnitude of head impacts associated with increased NF-L levels | [64] |
| • 14 boxers, 35 hockey players, 26 controls, bout +3 months | sNF-L | Simoa | High NF-L levels after bout, returned to normal after 3 mths + higher NF-L levels predicted longer post-concussion symptoms | [58] |
| **Spinal Cord Injury** | | | | |
| • 23 SCI (six cervical fracture, 17 whiplash) and 24 controls | CSF NF-L | ELISA | NF-L increased in proportion to neurological deficits | [65] |
| • 27 SCI and 67 controls | sNF-L | Simoa | Serum NF-L concentrations in SCI patients closely correlated with acute severity and long-term outcome | [66] |
| **Cardiac Arrest** | | | | |
| • 22 CA patients 2 or 3 weeks post-CA | CSF NF-L | ELISA | CSF NF-L levels were a reliable measure of brain damage and predictive of poor outcome | [67] |
| • 21 CA patients 2 weeks post-CA and 21 controls | CSF NF-L | ELISA | CSF NF-L levels increased in CA patients vs. controls. CSF NF-L levels highest in CA patients with poor outcome | [68] |
| • 14 CA patients within 17 days post-CA | sNF-L | Simoa | sNF-L levels associated with time to return of spontaneous circulation and brain damage. sNF-L levels were higher among CA patients who had died vs. CA patients alive at 1 months post-CA | [69] |
| Disease and Sample Size                                                                 | Protein | Method | Time Profile, Association with Disease Activity, and Diagnostic and/or Prognostic Relevance                                                                 | Reference |
|----------------------------------------------------------------------------------------|---------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 26 ROSC CA and 26 non-ROSC CA patients on admission                                     | s-pNF-H | ELISA  | No difference in pNF-H levels between ROSC and non-ROSC CA patients                                                                                   | [70]      |
| 90 CA patients treated with hypothermia sampled over a period of 72 h after CA         | p-pNF-H | ELISA  | p-pNF-H levels were higher at 2 and 36 h after CA in patients with poor outcome vs. those with good outcome. p-pNF-H levels correlated to neurological prognosis | [71]      |
| 717 CA patients sampled three times within the first 72 h after CA                      | sNF-L   | Simoa  | sNF-L levels were higher in patients with poor neurological outcome vs. those with good outcome                                                       | [72]      |
2. The Structure and Function of Neurofilament

NFs are present in the neuronal cytoskeleton, especially the axon, and are type IV intermediate filaments with a diameter of approximately 10 nm. These proteins are mostly found in adult myelinated neurons of the CNS and large-caliber myelinated axons of the PNS. NFs have several functions but are mainly responsible for increasing and maintaining axonal caliber and therefore improving relay of electrical impulses along the axons. Human NF is composed of four subunits: NF-L, neurofilament medium chain (NF-M), and neurofilament heavy chain (NF-H) with molecular weights of approximately 68, 160, and 205 kDa, respectively; the fourth subunit will depend on the location of the protein, therefore α-internexin (66 kDa), mostly present in spinal cord and optic nerve, is found in the CNS while peripherin (58 kDa), present in root ganglia neurons, is located in the PNS. NF chains are comprised of a non-helical amino terminal ‘head’ domain, a central α-helical ‘rod’ domain, and a variable length carboxyl terminal ‘tail’ domain [73–76]. Interference in NF assembly, metabolism, and release due to axonal injury is related to several neurodegenerative diseases, which is further elaborated on in this review.

3. Neurofilament in Neurological Disease

3.1. Peripheral Neuropathy

Peripheral neuropathy is a broad group of diseases that share the common feature of damage to peripheral nerves. Depending on the nerves affected, symptoms may include autonomic dysfunction, impaired sensation, or impaired movement. Onset of peripheral neuropathy can be acute, subacute, or chronic. Most peripheral neuropathies are acquired due to a large variety of underlying causes ranging from diabetes and alcohol abuse to inflammation and infection. A minority of peripheral neuropathies are hereditary.

NFs have mostly been associated with the hereditary neuropathies like Charcot–Marie–Tooth (CMT), in which several subtypes have been shown to include genetic mutations in the *NEFL* gene, leading to disruption of NF assembly and transport, and abnormal NF accumulation [77–81]. It is therefore not surprising that plasma NF-L is increased in CMT and correlates with disease severity in several subtypes [13].

The acquired neuropathies have also been the focus of NF studies. Serum NF-L is elevated in polyneuropathies as diverse as chronic inflammatory demyelinating polyneuropathy, anti-MAG neuropathy, and vasculitic neuropathy [10,11]. Serum levels were not only elevated compared to healthy controls but also seemed to decline with remission [11] and to correlate with disease severity and outcome [10].

In the case of Guillain–Barré syndrome (GBS), a rapidly evolving immune-mediated demyelinating polyradiculoneuropathy, axonal involvement is a well-known indicator of poor prognosis [82]. In line with this, CSF NF-L was not only elevated in the acute phase and correlated with disability [2] but was also a strong predictor of persistent disability [12]. These results were recently confirmed by plasma analyses [2,10].

Taken together, these studies suggest that NF-L might be a promising biomarker of disease and outcome in neuropathies. Studies of CMT often include large cohorts and sensitive detection methods. Although NF-L might have a role as a prognostic biomarker, its diagnostic sensitivity and specificity are most likely inferior to genetic testing.

In the acquired neuropathies, special care must be taken when interpreting results as studies are still limited by sample size and differences in detection technologies (Table 1). Further studies using reliable reproducible detection methods, like the Simoa technology, on larger cohorts are needed before final conclusions can be made.
3.2. Motor Neuron Disease

Motor neuron diseases (MNDs) are a group of neurodegenerative disorders characterized by degeneration of motor neurons. They comprise a spectrum of clinically defined diseases with involvement of upper and/or lower motor neurons and include progressive bulbar palsy, progressive muscular atrophy, primary lateral sclerosis, and some rare variants. The most common form of MND is ALS, a relentlessly progressive and ultimately lethal condition caused by degradation of lower and upper motor neurons in the motor cortex and spinal cord. Although most cases are sporadic, 5%–10% show a clear familial accumulation with a Mendelian pattern [83]. The diagnosis is made by classic clinical findings of progressive muscular paralysis, atrophy, fasciculations, and hyperreflexia, supported by electrophysiological findings. To better understand and predict the prognosis and to assist in the development of treatments, biomarkers in the blood and CSF have been intensely investigated.

Both NF-L and phosphorylated NF-H have been studied as possible biomarkers for ALS [14,16,84, 85]. Serum and plasma NF-L levels, tested using an ECL immunoassay, showed higher levels in ALS subjects compared to healthy controls as well as increased NF-L concentrations in ALS patients with a fast progressing phenotype, stabilizing over time [14]. Even in the early stages, where symptoms are still minor, NF-L in blood and CSF can distinguish ALS patients from healthy controls, but more importantly can also distinguish ALS from other MNDs with similar features but with much better prognosis [14,15,86,87].

Furthermore, high NF-L levels in both CSF and blood and NF-H in CSF were found in symptomatic ALS patients compared to asymptomatic genetic mutation carriers, whose levels were similar to healthy controls [16]. Interestingly, an increase in blood NF-L was observed in asymptomatic individuals as early as 12 months before symptom development, suggesting that neurodegeneration precedes symptom development [16].

As a prognostic marker, CSF NF-L levels are lower in patients with slower disease progression [88], and both serum and CSF NF-L as well as NF-H levels are associated with the number of muscular regions involved [89]. Similarly, serum and CSF NF-L levels are high in patients with rapid progression and shorter overall survival [17,85].

Apart from symptomatic treatment, disease-modifying therapies in MNDs are very limited, with riluzole being the only approved pharmacological therapy for ALS. A single study showed no difference in serum NF-H of patients on riluzole [84], but experiences from other diseases suggest that NFs might also be attractive candidates as endpoints in clinical trials in MNDs.

The studies on MNDs are generally solid, with large number of patients compared to appropriate controls (Table 1), and they suggest a role for NF-L as a diagnostic and prognostic marker, especially regarding measurements in the CSF. While measurements of NF-L in plasma or serum might be attractive, they must be evaluated with care and especially if less sensitive detection methods are applied. Considering the severity of these diseases, it is important to stress that NF-L elevations are a general feature of neurodegeneration and not specific to MND, thus results must be interpreted in the clinical context.

3.3. Multiple Sclerosis

Multiple sclerosis (MS) is a pathology characterized by continuous inflammation of the CNS that leads to demyelination of axons and consequent neurodegeneration. MS is often considered as either a relapsing-remitting disease or as a progressive disease with continuous disability progression, reflecting an ongoing underlying neurodegeneration. Diagnosis is made based on classical symptoms with dissemination in time and space, use of clinical biomarkers such as oligoclonal bands in CSF, magnetic resonance imaging (MRI), and exclusion of other plausible diseases [90–92]. In the past decade, however, the emergence of other biomarkers in CSF, like NF-L, has provided further insight into MS diagnosis and disease progression [93–96]. Several studies have shown that NF-L is elevated in the blood and CSF of newly diagnosed MS patients and that this is correlated with disease severity and prognosis [21,97–99]. NF-L is also elevated during disease activity such as a clinical relapse of
new lesions on MRI [100,101]. This makes NF-L an attractive diagnostic biomarker in MS although its specificity does not allow differentiation from MS mimics like neuromyelitis optica spectrum disorders or other neuroinflammatory disorders [102,103].

Repeated NF-L measures in the blood might be an attractive marker of treatment response since treatment with disease-modifying drugs such as dimethyl fumerate, interferon-beta, natalizumab, fingolimod, cladribine, and alemtuzumab resulted in significant reductions in NF-L in the CSF and blood [21,97,104–107].

Brain atrophy is also a well-known hallmark of the neurodegeneration seen in MS. It is therefore interesting that even early measures of blood NF-L in newly diagnosed MS patients can predict brain atrophy [22] and lesion load on MRI [23], probably reflecting high disease activity since this can be modified by initiation of effective treatment [108]. However, NF-L levels have shown poor correlation to disability scores such as the Extended Disability Status Scale (EDSS) [22–24,93,109,110]. This is most likely due to the emphasis on gait performance in the EDSS that may overestimate the influence of spinal cord lesions over cerebral lesions, which can be extensive even at low EDSS scores. Whether NF-L levels also correlate with cognitive measures and fatigue in MS remains to be confirmed although recent studies seem to suggest a negative correlation [23,111–113].

The study of NF-L is a rapidly growing field in MS, and studies are moving from CSF measurements to serum/plasma measurements using sensitive techniques. As a diagnostic marker, NF-L might not provide much additional value to the already applied diagnostics as its specificity does not allow differentiation from MS mimics. However, as a marker of disease activity and treatment response, repeated NF-L measurements in blood are moving towards an established biomarker with solid studies on large cohorts under various medications using sensitive techniques (Table 1). The focus has so far been on the relapsing-remitting phenotype where treatment options are many. However, NF-L might also be an attractive marker of disease activity in the progressive forms of MS, where neurodegeneration outweighs neuroinflammation, and it might provide assistance in clinical trials of new medications.

### 3.4. Alzheimer’s Disease

The neurodegenerative disorder of Alzheimer’s disease (AD) is the most frequent cause of dementia, accounting for 60%–80% of all cases [114]. The condition has many clinical features, the most essential being loss of memory. AD pathology is characterized by amyloid plaques originating from the amyloid precursor protein (APP) metabolism. Amyloid plaques in AD are abnormally folded Aβ40 or Aβ42 and are deposited extracellularly. Neurofibrillary tangles, which are also prominent in AD pathology, are made up of paired helical filaments composed of hyperphosphorylated tau, a microtubule-stabilizing protein. AD’s pathological processes lead to neurodegeneration and inflammation, causing neuronal and synaptic loss and progressive macroscopic atrophy [115,116]. 33r5453we32e23322w23443eSF and blood levels of tau, phospho-tau, and Aβ1-42 are used to solidify the diagnosis and to differentiate between AD and other forms of dementia [117–120]. With the complications associated with using CSF, several recent studies have turned to other proteins found in blood, like NF-L, to investigate their role in disease progression and neurodegeneration [27,28,30]. Most studies have revealed increased NF-L concentrations in patients with AD and other forms of dementia compared to healthy controls (Table 1). A particular study also noted that high NF-L levels in plasma of AD patients correlated with poor cognition and brain atrophy [30]. NF-L has also been used as a biomarker for cognition impairment, revealing that high NF-L plasma levels correlate with impaired cognition in AD, giving potential for this protein to be a biomarker for mental decline [31]. Down syndrome (DS) individuals have an increased risk of developing early-onset AD, with approximately two-thirds of all individuals being affected by this form of dementia [121]. NF-L plasma levels were indeed found to be higher in DS and seemed to increase with age and to predict dementia status [122]. A cross-sectional study on DS concluded that NF-L was useful in diagnosing AD in DS individuals and outperformed other fluid biomarkers [29]. All these studies mentioned used Simoa technology.
and concluded that NF-L is a potential non-invasive biomarker for AD, helping to solidify a diagnosis and monitor disease progression.

Given that cognitive impairment and particularly frontotemporal dementia (FTD) can be found in up to 10%–15% of patients with ALS [123], it is interesting that in this particular form of dementia, blood and CSF NF-L levels are associated with functional outcome, brain atrophy, and severity, and can be used to discern FTD from other types of dementia and healthy controls but not be used to distinguish between FTD subtypes [124–126]. However, the use of varied biomarker panels comprised of NF-L, total and phosphorylated tau, and $\beta_{1-42}$ improved discrimination between AD dementia, FTD, and some other types of dementia [118,127,128] and increased sensitivity in AD stage differentiation using NF-L and fatty acid binding protein 3 [129]. A panel of biomarkers that includes proteins involved in the pathogenic mechanisms of dementia helps improve diagnosis and clinical staging of the disease.

Taken together, the evidence so far supports NF-L in the CSF and blood as a diagnostic marker of dementia, with AD being most frequently investigated (Table 1). As the hallmark of dementia is ongoing neurodegeneration, it is not surprising that NFs are elevated. The specificity of NF-L is therefore also limited and is strongest as part of a varied biomarker panel. Especially in the aged population, data must be interpreted in the clinical context due to age-dependent variations in NF-L levels, which calls for special attention to the age-matched healthy controls provided in many of the studies listed in Table 1.

3.5. Huntington’s Disease

Huntington’s disease (HD) is a genetic neurodegenerative pathology where a CGA triplet repeat expansion on the huntingtin gene (HTT) originates as an expanded polyglutamine segment in the huntingtin protein. The expanded protein forms intranuclear aggregates toxic to neuronal cells, causing neuronal dysfunction and cell death. In HD, biomarkers have the potential role of assessing therapeutic efficacy, and most recently NF has been tested in both CSF and plasma [35,36,130,131] (Table 1). A recent study investigated the correlation between mutant huntingtin (mHTT) and CSF and plasma NF-L levels in HD patients, revealing NF-L to be a clinically stronger marker than mHTT, even within the study’s limitations [33]. ELISA showed that NF-L levels in CSF of HD patients were significantly higher than those in matched controls [36], while plasma levels of NF-H, using ELISA, excluded this NF subunit as a potential biomarker [130]. Most recently, a cohort analysis using highly sensitive Simoa showed great potential of plasma NF-L as a prognostic marker and as a timepoint reflection for motor and cognitive impairment [35]. The latest generation of quantitative methods could enable the use of NF-L as a stronger observational and therapeutic biomarker for HD. Genetic therapies combined with NF-L observation could be important tools in the treatment and monitoring of this pathology.

Studies on HD are limited and have small samples sizes, however, most likely due to the low prevalence of the disease. Further studies using sensitive techniques are therefore needed before conclusions can be made, especially considering measurements on peripheral blood. However, while the diagnostic value of NF-L is probably minor compared to genetic testing, NF-L might be a promising prognostic marker and may assist in the development of therapies by acting as a marker in clinical trials.

3.6. Parkinson’s Disease and Parkinsonian Disorders

Atypical parkinsonian disorders (APDs) such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD) often present with similar and overlapping symptomatology as Parkinson’s disease (PD), especially in early disease stages. CSF NF-L is a promising marker to separate PD from APD, as NF-L is increased in APD compared to PD [132,133] and can be used to discriminate between APD and PD with a high degree of accuracy [134–136] (Table 1). Blood NF-L has also recently been demonstrated to be a promising diagnostic marker to separate PD from APD, with significantly higher blood NF-L levels in APD patients compared to
PD patients and healthy controls [38,137]. As NF-L levels in PD patients are comparable to healthy controls, NF-L appears to be a better prognostic marker for APD than for PD. Given that NF-L is a marker of large myelinated axons, it is possible that axonal degeneration is less severe in PD than in APD so that blood NF-L does not increase in PD compared to healthy controls. This is in line with MRI diffusion studies demonstrating extensive white matter injury in APD but not in PD [138–140] and studies demonstrating that NF-L levels correlate with disease severity in APD [38,136,141].

As PD and APD are still largely clinical diagnoses, supportive biomarkers are highly sought. Evidence suggests that at least in the CSF, NF-L might be a strong candidate as a discriminating diagnostic biomarker. Sensitivity is diminished, however, when testing in the peripheral blood, stressing the need for reliable and sensitive detection methods and preferably Simoa technology (Table 1). The parkinsonian disorders show great variation in their clinical presentation, with various degrees of clinical symptoms including dementia. As an ongoing progressive disease, this calls for special attention in the matching of study populations with healthy controls and is often the weak point in studies of less common diseases with multiple subtypes. Further studies on larger cohorts are therefore required.

3.7. Stroke

Stroke is a leading cause of death and disability worldwide, making this condition a major health concern [142,143]. Neuronal death caused by deprivation of glucose and oxygen to the affected area leads to the release of axonal proteins, like NF. This protein has a potential for being a biomarker for stroke severity and post-stroke outcome. Studies have shown how the CSF NF-H levels, measured using ELISA, increased in aneurysmal hemorrhagic and acute ischemic stroke and related to patient outcome [55] (Table 1). One study assessed CSF NF-L levels along with a panel of other neuronal biomarkers that were measured in acute ischemic stroke patients, and found higher levels of this NF-L compared to controls as well as a correlation with the degree of white matter hyperintensities [46]. However, the emergence of more sensitive detection techniques has allowed the detection of NF-L in the peripheral blood. Serum NF-L levels, analyzed using Simoa, of patients with MRI-confirmed small subcortical infarcts were higher than in healthy controls [49] (Table 1). This trend continued at three months follow up, but NF-L levels seemed to normalize fifteen months post-stroke [49], indicating that NF-L could be a tool for monitoring infarct extent after a stroke. NF-L serum levels are higher in ischemic stroke cases than in healthy controls, while also differentiating between ischemic stroke and transient ischemic attack (Table 1). Higher NF-L levels were associated with more severe disability scores [44,45]. In a large prospective study, Pedersen et al. used Simoa to study the association between functional outcome and serum NF-L levels sampled within the first 1–14 days, 3 months, and 7 years after ischemic stroke [41]. The authors showed that serum NF-L levels increased with time between stroke and blood sampling and observed the highest concentrations at 3 months post-stroke. Serum NF-L levels correlated with functional outcome at all timepoints investigated although the strongest correlation was between functional outcome and NF-L levels sampled 3 months after stroke onset. Importantly, for all main etiological stroke subtypes, both acute serum NF-L and 3 month levels were significantly higher in stroke patients than in controls. The release of NF-L after acute neuronal damage could be due to continuous breakdown of the blood–brain barrier, but persistent post-ischemic inflammatory and immunological processes could also explain lengthened NF-L release [4]. Further studies on this research topic could help us understand the role of inflammation in stroke and axonal injury.

As stroke is a common disease, study populations are often large with well-matched control populations, providing strong evidence for NF-L as a diagnostic and prognostic marker. In contrast to the chronic diseases, stroke represents an acute neurodegeneration followed by a recovery phase with little or no ongoing neuronal pathology. NF-L levels are therefore likely to be time-dependent, with decreasing levels over time. This makes comparison between studies enrolling from 1 to 14 days post-stroke difficult, even when using the same sensitive and reliable detection method (Table 1).
Since very little is known about the dynamics of NF-L release after an acute pathology, this must be investigated further. An appropriate consensus time for measurement must be established before NF-L can be considered a reliable prognostic and diagnostic biomarker of stroke.

3.8. Traumatic Axonal Injury

Traumatic brain injury (TBI) is the principal cause of death and morbidity in individuals under 45 years old and is a topic of high concern [144]. TBI can be classified as mild, moderate, or severe, typically using the Glasgow Coma Scale (GCS) [145–147], with mild traumatic brain injury (GCS score 14–15) being the most common. There is a need for biomarkers that can assess severity and outcome in TBI as well as the risk of developing chronic traumatic encephalopathy due to repeated exposure to head trauma [59,60].

Being an unspecific marker of neurodegeneration and axonal damage, NF-L is a promising marker of injury in TBI (Table 1). In severe TBI, both CSF and serum NF-L sharply increase over the first 2 weeks compared to healthy controls and appear to be reliable predictors of poor outcome [56–58]. Similar predictions may be possible from serum NF-L in mild traumatic injury although care must be taken when patients are over 60 years old or have preexisting neurological disorders [59,60].

Most studies in mild TBI or concussion have focused on athletes in contact sports like boxing, hockey, or American football (Table 1). Uncomplicated concussion in soccer [148] or even American football and hockey [61] does not seem to affect NF-L in serum or CSF. Elevated levels of CSF and serum NF-L have been documented in boxers, however, especially if the trauma incurred during a fight resulted in measurable impact on the GCS [62] or was due to several blows to the head [149]. Furthermore, NF-L stayed elevated for a prolonged time [150] and was still elevated after 3 months, a clear predictor of post-concussion symptoms [58].

Regardless of the type of contact sport, there seems to be a relationship between NF-L levels and the frequency and magnitude of the head impact [58,61–64,151,152]. It is not yet clear, however, whether NF-L may serve as a biomarker for prediction of when it is safe to return to contact sports without the risk of permanent disability and chronic traumatic encephalopathy [153]. A potential clinical use for this biomarker would be to help clinicians decide whether a patient with TBI should undergo a head CT or MRI in the acute setting. Since the fluid dynamics of plasma and serum NF-L are not completely clear at this time, it is most likely to be used as part of a multipanel array [154].

Similar to TBI, a few studies of traumatic spinal cord injury have demonstrated increased NF-L values in both CSF [65] and serum [66], where early elevations correlated with motor outcome 3–12 months after trauma. However, this area is still largely unexplored.

As TBI is an area of keen interest, studies of NF-L as a prognostic marker are many and often include large patient cohorts (Table 1). The evidence strongly supports NF-L as a prognostic marker in severe TBI although very little is known about the dynamics of NF-L in the recovery period, and the optimal timepoint for measurement is yet to be established. Studies in mild TBI are often limited by smaller study populations and varying types of head trauma. Nevertheless, the focus on head injury in contact sports provides good opportunities for further studies on large cohorts of healthy young adults with similar trauma. With the growing use of Simoa technology, longitudinal studies of NF-L in peripheral blood may soon provide the necessary evidence to support the use of NF-L as a prognostic marker.

3.9. Cardiac Arrest

Cardiac arrest often leads to global cerebral ischemia, and irreversible brain damage is likely to occur by nine minutes after the cessation of blood flow to the brain. The prognosis of out-of-hospital cardiac arrest is poor, with less than 10% survival [155]. Prognostication of brain damage in patients surviving cardiac arrest currently relies mainly on clinical observations, electroencephalography, somatosensory evoked potential, and neuroimaging. However, CSF biomarkers such as NFs have proved valuable as predictors of brain damage and outcome after cardiac arrest [67,68] (Table 1).
CSF NF-L levels are increased in cardiac arrest patients 2–3 weeks after the arrest compared to healthy controls, and NF-L levels are significantly higher in patients with poor outcome compared to those with good outcome according to the Glasgow Outcome Scale, activities of daily living, and mini-mental state examination [68]. Plasma [71] and serum [69,72] NF levels have also been measured in cardiac arrest patients (Table 1). In a recent pilot study, Disanto and colleagues [69] used Simoa to detect serum NF-L within 17 days of cardiac arrest and found a positive association between serum NF-L levels and time to return of spontaneous circulation, severity of brain damage estimated by electroencephalogram, and clinical outcome (death status at 1 month). In a large prospective study, Moseby-Knappe et al. [72] used ELISA to establish the potential of serum NF-L as a prognostic marker of outcome after cardiac arrest. Blood samples were collected at 24, 48, and 72 h after return of spontaneous circulation in 717 patients, of whom 360 had a poor neurologic outcome at 6 months. Serum NF-L levels were significantly increased in patients with poor outcome compared to those with good outcome at all timepoints and performed better than the biochemical biomarkers tau, neuron-specific enolase, and S100. The authors concluded that serum NF-L can be used as a predictive marker of long-term poor neurological outcome at 24 h after cardiac arrest.

These findings suggest that NFs can be used as reliable measures of brain damage following cardiac arrest and that blood NF levels are highly predictive of outcome. As this area is relatively unexplored, studies are still scarce and flawed by low patient numbers and variations in the timing of measurement. Future studies will help determine the potential of NFs as future biomarkers after cardiac arrest.

3.10. Delirium

Delirium is a common and serious neuropsychiatric syndrome that manifests a new-onset dementia with features of inattention and global cognitive dysfunction. The etiological causes of delirium are many and multifactorial and often reflect ongoing acute medical illness or medical complication. Currently, the diagnosis of delirium is clinically based and depends on the absence or presence of certain features. As delirium appears to be associated with permanent encephalopathy with neuronal damage and/or dysfunction, several studies have investigated NFs as potential new biomarkers of neuroaxonal damage in delirium patients [156–161]. In a recent prospective, pilot observational study, Ehler and colleagues [161] demonstrated, using ELISA, that plasma NF-L levels increased in sepsis patients over time and remained stable in patients without sepsis. Furthermore, NF-L levels were higher in patients with sepsis-associated encephalopathy and correlated with functional outcome and death. Elderly hospitalized patients are at high risk of developing delirium and postoperative delirium appears to be associated with increased plasma NF-L levels [159]. The use of NFs as biomarkers in delirium is, however, still controversial as the literature in this field is still scarce. One study demonstrated that serum NF-L, measured using Simoa, increased significantly in patients that developed delirium after cardiac surgery [157], whereas in another study [158] serum NF-H, measured using ELISA, could not be used to predict patients at risk of delirium following cardiac surgery. Whether these results reflect differences in the sensitivity of the assay, ELISA vs. Simoa, differences in the NF investigated, NF-L vs. NF-H, or differences in the underlying disease mechanisms, remain to be elucidated. More studies are warranted to uncover the potential of NFs as biomarkers in delirium.

4. Discussion

NFs are often considered the C-reactive protein (CRP) test of neurology, suggesting its use as an unspecific screening marker of neurodegeneration in the PNS or CNS. However, like the CRP, care must be taken when interpreting results obtained in different studies. First, very little is known about NF levels and dynamics in the normal healthy population. Ideally, large populations of healthy individuals are required to generate normative data for reference use. While most studies compare diseased patients with normal healthy controls, many samples are collected from patients referred to hospital due to a complaint that is later resolved or not caused by neurological disease [97]. Such symptomatic controls
may not represent the true levels of NF in the general population. Second, many studies also show an age-dependent correlation with NFs [59,60,98]. This is most likely caused by the well-described physiological age-related brain atrophy [162,163]. Similarly, it has been claimed that the subjects’ sex may affect NF levels [164,165] although this remains to be verified. Third, variations in the source of the tested substance need to be considered. In neurological diseases, NF-L is often tested in CSF, serum, or plasma. While CSF has some obvious advantages in CNS disease, its use is often limited by the invasive nature of the procedure that precludes its use as a frequent longitudinal marker. In general, there are strong correlations between NF-L levels in CSF, serum, and plasma [97,101,166,167], but while specificity and sensitivity are high in CSF due to the higher levels of NF-L, sensitivity is often lower in plasma [101,164,166,168] and even lower in serum [97]. Finally, the test methods also affect the results. NF-L is typically measured using one of three assays. The commercially available ELISA [169] has the advantage of being cheap and is readily available in most laboratories, but the manufacturer does not recommended it for blood analyses because of its low sensitivity. ECL-based assays are sensitive and require only a small sample volume to produce a large range of results [2]. These methods have largely been replaced by the Simoa technology, however, as digital immunoassays can significantly improve sensitivity and deliver reliable and robust data on both CSF, serum, and plasma NF-L, even between different laboratories [97,141].

5. Conclusions

The development of extremely sensitive immunoassays has increased the potential role of NF-L as a biomarker through avoiding the collection of CSF and enabling frequent measurement in blood and not just the CSF. These ultrasensitive methods have allowed NF-L monitoring to expand to conditions where CSF collection might not be possible and allow repeated measures in longitudinal studies. Together with other clinical and paraclinical measures, NF-L may be able to contribute to diagnosis, improving accuracy, and differentiating between manifestations and stages of certain diseases. However, just as the CRP is an unspecific test of inflammation and disease activity, NF-L must be interpreted in the clinical context, and no single test or value can be used to rule in or out a specific diagnosis. Without normative data for the general population and with various techniques still being applied, care must be taken when interpreting NF levels as predictors of or biomarkers for neurological diseases. Future studies using sensitive and reproducible techniques are needed to further solidify this protein before fully applying it to clinical practice.

Author Contributions: C.B.S., K.L.L. and H.H.N. wrote the manuscript with the assistance of D.G. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the Danish Council for Independent Research, Medical Sciences (DFF-4183-00033 to KLL) and the Danish Neurological Society (KLL).

Acknowledgments: Bente Finsen is acknowledged for providing tissue sections stained immunohistochemically for NF-H chain. Claire Gudex is acknowledged for proofreading the manuscript.

Conflicts of Interest: K.L.L. is a member of the Lundbeck Foundation Brain Prize Council. H.H.N. is a member of the research council of the Danish Multiple Sclerosis Society and has served on scientific advisory boards and received support for congress participation, speaker honoraria, and research support from Biogen, Merck-Serono, Roche, Teva, Lundbeck, and Novartis.
Abbreviations

AD Alzheimer’s disease
ALS amyotrophic lateral sclerosis
APD atypical parkinsonian disorder
APP amyloid precursor protein
CBG corticobasal degeneration
CSF cerebrospinal fluid
CMT Charcot–Marie–Tooth
CNS central nervous system
CRP C-reactive protein
DS Down syndrome
ECL electrochemiluminescence
EDSS Extended Disability Status Scale
FTD frontotemporal dementia
GBS Guillain–Barré syndrome
GCS Glasgow Coma Scale
HD Huntington’s disease
HTT huntingtin gene
mHTT mutant huntingtin gene
MND motor neuron disease
MRI magnetic resonance imaging
MS multiple sclerosis
MSA multiple system atrophy
NF neurofilament
NF-H neurofilament heavy chain
NF-L neurofilament light chain
NF-M neurofilament medium chain
PD Parkinson’s disease
PNS peripheral nervous system
PSP progressive supranuclear palsy
Simoa single molecule array technology
TBI traumatic brain injury

References

1. Rosengren, L.E.; Karlsson, J.E.; Karlsson, J.O.; Persson, L.I.; Wikkelso, C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. *J. Neurochem.* **1996**, *67*, 2013–2018. [CrossRef]

2. Gaiottino, J.; Norgren, N.; Dobson, R.; Topping, J.; Nissim, A.; Malaspina, A.; Bestwick, J.P.; Monsch, A.U.; Regeniter, A.; Lindberg, R.L.; et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. *PLoS ONE* **2013**, *8*, e75091. [CrossRef]

3. Rissin, D.M.; Kan, C.W.; Campbell, T.G.; Howes, S.C.; Fournier, D.R.; Song, L.; Piech, T.; Patel, P.P.; Chang, L.; Rivnak, A.J.; et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. *Nat. Biotechnol.* **2010**, *28*, 595–599. [CrossRef]

4. Khalil, M.; Teunissen, C.E.; Otto, M.; Piehl, F.; Sormani, M.P.; Gattringer, T.; Barro, C.; Kappos, L.; Comabella, M.; Fazekas, F.; et al. Neurofilaments as biomarkers in neurological disorders. *Nat. Rev. Neurol.* **2018**, *14*, 577–589. [CrossRef]

5. Gisslen, M.; Price, R.W.; Andreasson, U.; Norgren, N.; Nilsson, S.; Hagberg, L.; Fuchs, D.; Spudich, S.; Blennow, K.; Zetterberg, H. Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study. *EBioMedicine* **2016**, *3*, 135–140. [CrossRef]

6. Lambertsen, K.L.; Finsen, B.; Clausen, B.H. Post-stroke inflammation-target or tool for therapy? *Acta Neuropathol.* **2018**, [CrossRef]
7. Clausen, B.H.; Lambertsen, K.L.; Dagnaes-Hansen, F.; Babcock, A.A.; von Linstow, C.U.; Meldgaard, M.; Kristensen, B.W.; Deierborg, T.; Finsen, B. Cell therapy centered on IL-1Ra is neuroprotective in experimental stroke. *Acta Neuropathol.* 2016. [CrossRef]

8. Clausen, B.H.; Degn, M.; Sivasaravanaparan, M.; Fogtmann, T.; Andersen, M.G.; Trojanowsky, M.D.; Gao, H.; Hvidsten, S.; Baun, C.; Deierborg, T.; et al. Conditional ablation of myeloid TNF increases lesion volume after experimental stroke in mice, possibly via altered ERK1/2 signaling. *Sci. Rep.* 2016, 6, 29291. [CrossRef]

9. Lambertsen, K.L.; Ostergaard, K.; Clausen, B.H.; Hansen, S.; Stenvang, J.; Thorsen, S.B.; Meldgaard, M.; Kristensen, B.W.; Hansen, P.B.; Sorensen, G.L.; et al. No effect of ablation of surfactant protein-D on acute cerebral infarction in mice. *J. Neuroinflammation* 2014, 11, 123. [CrossRef]

10. Mariotto, S.; Farinazzo, A.; Magliozzi, R.; Alberti, D.; Monaco, S.; Ferrari, S. Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies. *J. Peripher. Nerv. Syst.* 2018, 23, 174–177. [CrossRef]

11. Bischof, A.; Manigold, T.; Barro, C.; Heijnen, I.; Berger, C.T.; Derfuss, T.; Kuhle, J.; Daikeler, T. Serum neurofilament light chain: A biomarker of neuronal injury in vasculitic neuropathy. *Ann. Rheum. Dis.* 2018, 77, 1093–1094. [CrossRef]

12. Axelsson, M.; Sjogren, M.; Andersen, O.; Blennow, K.; Zetterberg, H.; Lycke, J. Neurofilament light protein levels in cerebrospinal fluid predict long-term disability of Guillain-Barre syndrome: A pilot study. *Acta Neurol. Scand.* 2018, 138, 143–150. [CrossRef]

13. Sandelius, A.; Zetterberg, H.; Blennow, K.; Adiutori, R.; Malaspina, A.; Laura, M.; Reilly, M.M.; Rossor, A.M. Plasma neurofilament light chain levels in patients with the inherited peripheral neuropathies. *Neurology* 2018, 90, e518–e524. [CrossRef]

14. Lu, C.H.; Macdonald-Wallis, C.; Gray, E.; Pearce, N.; Petzold, A.; Norgren, N.; Giovannoni, G.; Fratta, P.; Sidle, K.; Fish, M.; et al. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. *Neurology* 2015, 84, 2247–2257. [CrossRef]

15. Verde, F.; Steinacker, P.; Weishaupt, J.H.; Kassubek, J.; Oeckl, P.; Halbgebauer, S.; Tumani, H.; von Arnim, C.A.F.; Dorst, J.; Feneberg, E.; et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. *J. Neurol. Neurosurg. Psychiatry* 2019, 90, 157–164. [CrossRef]

16. Weydt, P.; Oeckl, P.; Huss, A.; Muller, K.; Volk, A.E.; Kuhle, J.; Knehr, A.; Andersen, P.M.; Prudlo, J.; Steinacker, P.; et al. Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. *Ann. Neurol.* 2016, 79, 152–158. [CrossRef]

17. Skillback, T.; Mattsson, N.; Blennow, K.; Zetterberg, H. Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival. *Amyotroph. Lateral Scler. Front. Degener.* 2017, 18, 397–403. [CrossRef]

18. Modvig, S.; Degn, M.; Horwitz, H.; Cramer, S.P.; Larsson, H.B.; Wanscher, B.; Sellebjerg, F.; Frederiksen, J.L. Relationship between cerebrospinal fluid biomarkers for inflammation, demyelination and neurodegeneration in acute optic neuritis. *PLoS ONE* 2013, 8, e77163. [CrossRef]

19. Modvig, S.; Degn, M.; Sander, B.; Horwitz, H.; Wanscher, B.; Sellebjerg, F.; Frederiksen, J.L. Cerebrospinal fluid neurofilament light chain levels predict visual outcome after optic neuritis. *Mult. Scler.* 2016, 22, 590–598. [CrossRef]

20. Modvig, S.; Degn, M.; Roed, H.; Sorensen, T.L.; Larsson, H.B.; Langkilde, A.R.; Frederiksen, J.L.; Sellebjerg, F. Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis. *Mult. Scler.* 2015, 21, 1761–1770. [CrossRef]

21. Kuhle, J.; Kropshofer, H.; Haering, D.A.; Kundu, U.; Meinert, R.; Barro, C.; Dahlke, F.; Tomic, D.; Leppert, D.; Kappos, L. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. *Neurology* 2019, 92, e1007–e1015. [CrossRef]

22. Siller, N.; Kuhle, J.; Muthuraman, M.; Barro, C.; Uphant, T.; Groppa, S.; Kappos, L.; Zipp, F.; Bittner, S. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. *Mult. Scler.* 2019, 25, 678–686. [CrossRef]

23. Chitnis, T.; Gonzalez, C.; Healy, B.C.; Saxena, S.; Rosso, M.; Barro, C.; Michalak, Z.; Paul, A.; Kivisakk, P.; Diaz-Cruz, C.; et al. Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis. *Ann. Clin. Transl. Neurol.* 2018, 5, 1478–1491. [CrossRef]
24. Barro, C.; Benkert, P.; Disanto, G.; Tsagkas, C.; Aman, M.; Naegelin, Y.; Leppert, D.; Gobbi, C.; Granziera, C.; Yaldizli, O.; et al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. *Brain* 2018, 141, 2382–2391. [CrossRef]

25. Sanchez-Valle, R.; Heslegrave, A.; Foiani, M.S.; Bosch, B.; Antonell, A.; Balasa, M.; Llado, A.; Zetterberg, H.; Fox, N.C. Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer’s disease. *Alzheimers Res. Ther.* 2018, 10, 113. [CrossRef]

26. Preische, O.; Schultz, S.A.; Apel, A.; Kuhle, J.; Kaeser, S.A.; Barro, C.; Graber, S.; Kuder-Bulettu, E.; LaFougere, C.; Laske, C.; et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease. *Nat. Med.* 2019, 25, 277–283. [CrossRef]

27. Zhou, W.; Zhang, J.; Ye, F.; Xu, G.; Su, H.; Su, Y.; Zhang, X.; Alzheimer’s Disease Neuroimaging. I. Plasma neurofilament light chain levels in Alzheimer’s disease. *Neurosci. Lett.* 2017, 650, 60–64. [CrossRef]

28. Lewczuk, P.; Ermann, N.; Andreasson, U.; Schultheis, C.; Podhorna, J.; Spitzer, P.; Maler, J.M.; Kornhuber, J.; Blennow, K.; Zetterberg, H. Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease. *Alzheimers Res. Ther.* 2018, 10, 71. [CrossRef]

29. Fortea, J.; Carmona-Iragui, M.; Benejam, B.; Fernandez, S.; Videla, L.; Barroeta, I.; Alcolea, D.; Pegueroles, J.; Munoz, L.; Belbin, O.; et al. Plasma and CSF biomarkers for the diagnosis of Alzheimer’s disease in adults with Down syndrome: A cross-sectional study. *Lancet Neurol.* 2018, 17, 860–869. [CrossRef]

30. Mattsson, N.; Andreasson, U.; Zetterberg, H.; Blennow, K. Association of Plasma Neurofilament Light with Neurodegeneration in Patients with Alzheimer Disease. *JAMA Neurol.* 2017, 74, 557–566. [CrossRef]

31. Lin, Y.S.; Lee, W.J.; Wang, S.J.; Fuh, J.L. Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease. *Sci. Rep.* 2018, 8, 17368. [CrossRef]

32. Niemela, V.; Landblom, A.M.; Blennow, K.; Sundblom, J. Tau or neurofilament light-Which is the more suitable biomarker for Huntington’s disease? *PloS ONE* 2017, 12, e0172762. [CrossRef]

33. Byrne, L.M.; Rodrigues, F.B.; Johnson, E.B.; Wijeratne, P.A.; De Vita, E.; Alexander, D.C.; Palermo, G.; Czech, C.; Schoebel, S.; Scabill, R.I.; et al. Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington’s disease. *Sci. Transl. Med.* 2018, 10. [CrossRef]

34. Wild, E.J.; Petzold, A.; Keir, G.; Tabrizi, S.J. Plasma neurofilament heavy chain levels in Huntington’s disease. *Neurosci. Lett.* 2007, 417, 231–233. [CrossRef]

35. Byrne, L.M.; Rodrigues, F.B.; Blennow, K.; Durr, A.; Leavitt, B.R.; Roos, R.A.C.; Scahill, R.I.; Tabrizi, S.J.; Zetterberg, H.; Langbehn, D.; et al. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington’s disease. *Lancet Neurol.* 2017, 16, 601–609. [CrossRef]

36. Constantinescu, R.; Romer, M.; Oakes, D.; Rosengren, L.; Kieburtz, K. Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington’s disease. *Parkinsonism Relat. Disord.* 2009, 15, 245–248. [CrossRef]

37. Vinther-Jensen, T.; Borrsen, L.; Budtz-Jorgensen, E.; Ammitzboll, C.; Larsen, I.U.; Hjermind, L.E.; Sellebjerg, F.; Nielsen, J.E. Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease. *NeuroInf. Immunol. Neuroinflamm.* 2016, 3, e287. [CrossRef]

38. Hansson, O.; Janelidze, S.; Hall, S.; Magdalino, N.; Lees, A.J.; Andreasson, U.; Norgren, L.; Linder, J.; Forsgren, L.; Constantinescu, R.; et al. Blood-based NFL: A biomarker for differential diagnosis of parkinsonian disorder. *Neurology* 2017, 88, 930–937. [CrossRef]

39. Hall, S.; Surova, Y.; Ohrfelt, A.; Swedish Bio, F.S.; Blennow, K.; Zetterberg, H.; Hansson, O. Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson’s Disease. *Mov. Disord.* 2016, 31, 898–905. [CrossRef]

40. Constantinescu, R.; Rosengren, L.; Erikson, B.; Blennow, K.; Axelsson, M. Cerebrospinal fluid neurofilament light and tau protein as mortality biomarkers in parkinsonism. *Acta Neurol. Scand.* 2019, 140, 147–156. [CrossRef]

41. Pedersen, A.; Stanne, T.M.; Nilsson, S.; Klasson, S.; Rosengren, L.; Holmegaard, L.; Joed, K.; Blennow, K.; Zetterberg, H.; Jern, C. Circulating neurofilament light in ischemic stroke: Temporal profile and outcome prediction. *J. Neurol.* 2019, 266, 2796–2806. [CrossRef]

42. Onatsu, J.; Vanninen, R.; Jakala, P.; Mustonen, P.; Pulkki, K.; Korhonen, M.; Hedman, M.; Zetterberg, H.; Blennow, K.; Hoglund, K.; et al. Serum Neurofilament Light Chain Concentration Correlates with Infarct Volume but Not Prognosis in Acute Ischemic Stroke. *J. Stroke Cerebrovasc. Dis.* 2019, 28, 2242–2249. [CrossRef]
43. Singh, P.; Yan, J.; Hull, R.; Read, S.; O’Sullivan, J.; Henderson, R.D.; Rose, S.; Greer, J.M.; McCombe, P.A. Levels of phosphorylated axonal neurofilament subunit H (pNfH) are increased in acute ischemic stroke. *J. Neurol. Sci.* 2011, 304, 117–121. [CrossRef]

44. De Marchis, G.M.; Katan, M.; Barro, C.; Flad, J.; Traenka, C.; Seiiffge, D.J.; Hert, L.; Gensicke, H.; Disanto, G.; Sutter, R.; et al. Serum neurofilament light chain in patients with acute cerebrovascular events. *Eur. J. Neurol.* 2018, 25, 562–568. [CrossRef]

45. Petzold, A.; Michel, P.; Stock, M.; Schluep, M. Glial and axonal body fluid biomarkers are related to infarct volume, severity, and outcome. *J. Stroke Cerebrovasc. Dis.* 2008, 17, 196–203. [CrossRef] [PubMed]

46. Jonsson, M.; Zetterberg, H.; van Straaten, E.; Lind, K.; Syversen, S.; Edman, A.; Blennow, K.; Rosengren, L.; Pantoni, L.; Inzitari, D.; et al. Cerebrospinal fluid biomarkers of white matter lesions—Cross-sectional characteristics and Outcome in Patients with Cervical Artery Dissection. *Cerebrovasc. Dis.* 2015, 40, 222–227. [CrossRef]

47. Martinez-Morillo, E.; Childs, C.; Garcia, B.P.; Alvarez Menendez, F.V.; Romaschin, A.D.; Cervellin, G.; Lippi, G.; Diamandis, E.P. Neurofilament medium polypeptide (NFM) protein concentration is increased in CSF and serum samples from patients with brain injury. *Clin. Chem. Lab. Med.* 2015, 53, 1575–1584. [CrossRef]

48. Grobke, S.; Voortman, M.; et al. Serum neurofilament light is sensitive to active cerebral small vessel disease. *Neurology* 2017, 89, 2108–2114. [CrossRef]

49. Grobke, S.; Voortman, M.; et al. Serum neurofilament light chain is related to small vessel disease. *J. Stroke* 2018, 20, 228–238. [CrossRef] [PubMed]

50. Lewis, S.B.; Wolper, R.A.; Miralia, L.; Yang, C.; Shaw, G. Detection of phosphorylated NF-H in the cerebrospinal fluid and blood of aneurysmal subarachnoid hemorrhage. *J. Neurol. Neurosurg. Psychiatry* 2011, 82, 157–161. [CrossRef] [PubMed]

51. Shahim, P.; Zetterberg, H.; Tegner, Y.; Blennow, K. Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports. *Neurology* 2017, 88, 1788–1794. [CrossRef] [PubMed]

52. Al Nimer, F.; Hjalmarsson, C.; Bjerke, M.; Andersson, B.; Blennow, K.; Zetterberg, H.; Aberg, N.D.; Olsson, B.; Eckerstrom, C.; Bokemark, L.; Wallin, A. Neuronal and glia-related biomarkers in cerebrospinal fluid of patients with acute ischemic stroke. *J. Cent. Nerv. Syst. Dis.* 2014, 6, 51–58. [CrossRef] [PubMed]

53. Kloss, M.; De Marchis, G.M.; et al. Serum Neurofilament Light Chain Levels Are Associated with Clinical Characteristics and Outcome in Patients with Cerebral Artery Dissection. *Cerebrovasc. Dis.* 2015, 40, 222–227. [CrossRef] [PubMed]
Charcot-Marie-Tooth disease-linked mutations in NFL and HSPB1. *Hum. Mol. Genet.* **2007**, *16*, 3103–3116. [CrossRef]

80. Tradewell, M.L.; Durham, H.D.; Mushynski, W.E.; Gentil, B.J. Mitochondrial and axonal abnormalities precede disruption of the neurofilament network in a model of charcot-marie-tooth disease type 2E and are prevented by heat shock proteins in a mutant-specific fashion. *J. Neuropathol. Exp. Neurol.* **2009**, *68*, 642–652. [CrossRef]

81. Yates, D.M.; Manser, C.; De Vos, K.J.; Shaw, C.E.; McLoughlin, D.M.; Miller, C.C. Neurofilament subunit (NFL) head domain phosphorylation regulates axonal transport of neurofilaments. *Eur. J. Cell Biol.* **2009**, *88*, 193–202. [CrossRef] [PubMed]

82. Estrade, S.; Guiomard, C.; Fabry, V.; Baudou, E.; Cances, C.; Chaix, Y.; Cintas, P.; Meyer, P.; Cheuret, E. Prognostic factors for the sequelae and severity of Guillain-Barre syndrome in children. *Muscle Nerve* **2019**, *60*, 716–723. [CrossRef] [PubMed]

83. Zou, Z.Y.; Zhou, Z.R.; Che, C.H.; Liu, C.Y.; He, R.L.; Huang, H.P. Genetic epidemiology of amyotrophic lateral sclerosis: A systematic review and meta-analysis. *J. Neurol. Neurosurg. Psychiatry* **2017**, *88*, 540–549. [CrossRef] [PubMed]

84. McCombe, P.A.; Pfluger, C.; Singh, P.; Lim, C.Y.; Airey, C.; Henderson, R.D. Serial measurements of phosphorylated neurofilament-heavy in the serum of subjects with amyotrophic lateral sclerosis. *J. Neurol. Sci.* **2015**, *353*, 122–129. [CrossRef]

85. Steinacker, P.; Feneberg, E.; Oeckl, P.; Steinacker, P.; Verde, F.; Barro, C.; Van Damme, P.; Gray, E.; Grosskreutz, J.; Jardel, C.; Kuhle, J.; et al. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. *Neurology* **2018**, *90*, e22–e30. [CrossRef]

86. Comabella, M.; Montalban, X. Body fluid biomarkers in multiple sclerosis. *Lancet Neurol.* **2014**, *13*, 113–126. [CrossRef] [PubMed]

87. Thouvenot, E. Multiple sclerosis biomarkers: Helping the diagnosis? *Rev. Neurol.* **2018**, *174*, 364–371. [CrossRef]

88. Kuhle, J.; Leppert, D.; Petzold, A.; Regeniter, A.; Schindler, C.; Mehling, M.; Anthony, D.C.; Kappos, L.; Lindberg, R.L. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. *Neurology* **2011**, *76*, 1206–1213. [CrossRef] [PubMed]

89. Martinez, M.A.; Olsson, B.; Bau, L.; Matas, E.; Cobo Calvo, A.; Andreasson, U.; Blennow, K.; Romero-Pinel, L.; Martinez-Yelamos, S.; Zetterberg, H. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. *Mult. Scler.* **2015**, *21*, 550–561. [CrossRef] [PubMed]

90. Bergman, J.; Dring, A.; Zetterberg, H.; Blennow, K.; Norgren, N.; Gilthorpe, J.; Bergenheim, T.; Svenningsson, A. Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS. *Neurol. Neuroimmunol. Neuroinflamm.* **2016**, *3*, e271. [CrossRef] [PubMed]

91. Pawlitzki, M.; Sweeney-Reed, C.M.; Bittner, D.; Lux, A.; Vielhaber, S.; Schreiber, S.; Paul, F.; Neumann, J. CSF-Progranulin and Neurofilament Light Chain Levels in Patients with Radiologically Isolated Syndrome-Sign of Inflammation. *Front. Neurol.* **2018**, *9*, 1075. [CrossRef]
97. Sejbaek, T.; Nielsen, H.H.; Penner, N.; Plavina, T.; Mendoza, J.P.; Martin, N.A.; Elkjaer, M.L.; Ravnborg, M.H.; Illes, Z. Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naive relapsing MS patients. J. Neurol. Neurosurg. Psychiatry 2019, 90, 1324–1330. [CrossRef]

98. Disanto, G.; Barro, C.; Benkert, P.; Naegelin, Y.; Schadelin, S.; Giardiello, A.; Zecca, C.; Blennow, K.; Zetterberg, H.; Leppert, D.; et al. Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann. Neurol. 2017. [CrossRef]

99. Lycke, J.; Karlsson, J.; E.; Andersen, O.; Rosengren, L.E. Neurofilament protein in cerebrospinal fluid: A potential marker of activity in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 1998, 64, 402–404. [CrossRef]

100. Damasceno, A.; Dias-Carneiro, R.P.C.; Moraes, A.S.; Boldrini, V.O.; Quintiliano, R.P.S.; da Silva, V.; Farias, A.S.; Brandao, C.O.; Damasceno, B.P.; Dos Santos, L.M.B.; et al. Clinical and MRI correlates of CSF neurofilament light chain levels in relapsing and progressive MS. Mult. Scler. Relat. Disord. 2019, 30, 149–153. [CrossRef]

101. Novakova, L.; Axelsson, M.; Malmstrom, C.; Imberg, H.; Elias, O.; Zetterberg, H.; Nerman, O.; Lycke, J. Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers. PLoS ONE 2018, 13, e0194828. [CrossRef] [PubMed]

102. Peng, L.; Bi, C.; Xia, D.; Mao, L.; Qian, H. Increased cerebrospinal fluid neurofilament light chain in central nervous system inflammatory demyelinating disease. Mult. Scler. Relat. Disord. 2019, 30, 123–128. [CrossRef] [PubMed]

103. Mariotto, S.; Ferrari, S.; Gastaldi, M.; Franciotta, D.; Sechi, E.; Capra, R.; Mancinelli, C.; Schanda, K.; Alberti, D.; Orlandi, R.; et al. Neurofilament light chain serum levels reflect disease severity in MOG-Ab associated disorders. J. Neurol. Neurosurg. Psychiatry 2019, 90, 1293–1296. [CrossRef] [PubMed]

104. Yildiz, O.; Mao, Z.; Adams, A.; Dubuisson, N.; Allen-Philbey, K.; Giovannoni, G.; Malaspina, A.; Baker, D.; Gnanapavan, S.; Schmierer, K. Disease activity in progressive multiple sclerosis can be effectively reduced by cladribine. Mult. Scler. Relat. Disord. 2018, 24, 20–27. [CrossRef] [PubMed]

105. Piehl, F.; Kockum, I.; Khademi, M.; Blennow, K.; Lycke, J.; Zetterberg, H.; Olsson, T. Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. Mult. Scler. 2018, 24, 1046–1054. [CrossRef] [PubMed]

106. Novakova, L.; Axelsson, M.; Malmstrom, C.; Imberg, H.; Elias, O.; Zetterberg, H.; Olsson, B.; Blennow, K.; Lycke, J. Serum and cerebrospinal fluid levels of neurofilament light: A potential therapeutic monitoring biomarker for multiple sclerosis. Mult. Scler. Relat. Disord. 2019, 30, 149–153. [CrossRef] [PubMed]

107. Hyun, J.W.; Kim, Y.; Kim, G.; Kim, S.H.; Kim, H.J. Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis. Mult. Scler. 2019. [CrossRef]

108. Melligard, J.; Tisell, A.; Blystad, I.; Gronqvist, A.; Blennow, K.; Olsson, B.; Dahlé, C.; Vrethem, M.; Lundberg, P.; Ernerudh, J. Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis. Eur. J. Neurol. 2017, 24, 112–121. [CrossRef]

109. Bhan, A.; Jacobsen, C.; Myhr, K.; Dalen, I.; Lode, K.; Farbu, E. Neurofilaments and 10-year follow-up in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2019, 90, 59–70. [CrossRef] [PubMed]

110. Pawlitzki, M.; Schreiber, S.; Kreipe, J.; Leyboldt, F.; Rupprecht, K.; Carare, R.O.; Meuth, S.G.; Vielhaber, S.; Kortvelyessy, P. CSF Neurofilament Light Chain Levels in Primary Progressive MS: Signs of Axonal Neurodegeneration. Front. Neurol. 2018, 9, 1037. [CrossRef]

111. Kalatha, T.; Arnaoutoglou, M.; Koukoulidis, T.; Hatzifilippou, E.; Bouras, E.; Baloyannis, S.; Koutsouraki, E. Does cognitive dysfunction correlate with neurofilament light polypeptide levels in the CSF of patients with multiple sclerosis? J. Int. Med. Res. 2019, 47, 2187–2198. [CrossRef]

112. Jakimovski, D.; Zivadinov, R.; Ramanthan, M.; Hagemeier, J.; Weinstock-Guttman, B.; Tomic, D.; Kropphofer, H.; Fuchs, T.A.; Barro, C.; Leppert, D.; et al. Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study. Mult. Scler. 2019. [CrossRef] [PubMed]

113. Hakansson, I.; Johansson, L.; Dahle, C.; Vrethem, M.; Ernerudh, J. Fatigue scores correlate with other self-assessment data, but not with clinical and biomarker parameters, in CIS and RRMS. Mult. Scler. Relat. Disord. 2019, 36, 101424. [CrossRef] [PubMed]

114. Alzheimer’s Association. 2016 Alzheimer’s disease facts and figures. Alzheimers Dement. 2016, 12, 459–509. [CrossRef] [PubMed]

115. Lane, C.A.; Hardy, J.; Schott, J.M. Alzheimer’s disease. Eur. J. Neurol. 2018, 25, 59–70. [CrossRef] [PubMed]
116. Spangenberg, E.E.; Green, K.N. Inflammation in Alzheimer’s disease: Lessons learned from microglia-depletion models. *Brain Behav. Immun.* 2017, 61, 1–11. [CrossRef]

117. Mantzavinos, V.; Alexiou, A. Biomarkers for Alzheimer’s Disease Diagnosis. *Curr. Alzheimer Res.* 2017, 14, 1149–1154. [CrossRef] [PubMed]

118. Hampel, H.; Toschi, N.; Baldacci, F.; Zetterberg, H.; Blennow, K.; Kilimann, I.; Teipel, S.J.; Cavedo, E.; Melo Dos Santos, A.; Epelbaum, S.; et al. Alzheimer’s disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Abeta1-42, total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40. *Alzheimers Dement.* 2018, 14, 492–501. [CrossRef]

119. Lue, L.F.; Guerra, A.; Walker, D.G. Amyloid Beta and Tau as Alzheimer’s Disease Blood Biomarkers: Promise From New Technologies. *Neurol. Ther.* 2017, 6, 25–36. [CrossRef]

120. Zetterberg, H. Applying fluid biomarkers to Alzheimer’s disease. *Am. J. Physiol. Cell Physiol.* 2017, 313, C3–C10. [CrossRef]

121. Wiseman, F.K.; Al-Janabi, T.; Hardy, J.; Karmiloff-Smith, A.; Nizetic, D.; Tybulewicz, V.L.; Fisher, E.M.; Strydom, A. A genetic cause of Alzheimer disease: Mechanistic insights from Down syndrome. *Nat. Rev. Neurosci.* 2015, 16, 564–574. [CrossRef] [PubMed]

122. Strydom, A.; Heslegrave, A.; Startin, C.M.; Mok, K.Y.; Hardy, J.; Groet, J.; Nizetic, D.; Zetterberg, H.; LonDown, S.C. Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome. *Alzheimers Res. Ther.* 2018, 10, 39. [CrossRef] [PubMed]

123. Ringholz, G.M.; Appel, S.H.; Bradshaw, M.; Cooke, N.A.; Mosnik, D.M.; Schulz, P.E. Prevalence and patterns of cognitive impairment in sporadic ALS. *Neurology* 2005, 65, 586–590. [CrossRef] [PubMed]

124. Steinacker, P.; Anderl-Straub, S.; Diehl-Schmid, J.; Semler, E.; Uttner, I.; von Arnim, C.A.F.; Barthel, H.; Danek, A.; Fassbender, K.; Fliesbach, K.; et al. Serum neurofilament light chain in behavioral variant frontotemporal dementia. *Neurology* 2018, 91, e1390–e1401. [CrossRef] [PubMed]

125. Ljubenkov, P.A.; Staffaroni, A.M.; Rojas, J.C.; Allen, I.E.; Wang, P.; Heuer, H.; Karydas, A.; Kornak, J.; Cobigo, Y.; Seeley, W.W.; et al. Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory. *Ann. Clin. Transl. Neural.* 2018, 5, 1250–1263. [CrossRef] [PubMed]

126. Meeter, L.H.H.; Vijverberg, E.G.; Del Campo, M.; Rozemuller, A.J.M.; Donker Kaat, L.; de Jong, F.J.; van der Flier, W.M.; Teunissen, C.E.; van Swieten, J.C.; Pijnenburg, Y.A.L. Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. *Neurology* 2018, 90, e1231–e1239. [CrossRef]

127. Paterson, R.W.; Slattery, C.F.; Poole, T.; Nicholas, J.M.; Magdalinou, N.K.; Toombs, J.; Chapman, M.D.; Lunn, M.P.; Heslegrave, A.J.; Foiani, M.S.; et al. Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory. *Alzheimers Res. Ther.* 2018, 10, 32. [CrossRef]

128. Abu-Rumeileh, S.; Mometto, N.; Bartoletti-Stella, A.; Polischi, B.; Oppi, F.; Poda, R.; Stanzani-Maserati, M.; Cortelli, P.; Liguori, R.; Capellari, S.; et al. Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study. *J. Alzheimers Dis.* 2018, 66, 551–563. [CrossRef]

129. Gangishetti, U.; Christina Howell, J.; Perrin, R.J.; Louneva, N.; Watts, K.D.; Kollhoff, A.; Grossman, M.; Wolk, D.A.; Shaw, L.M.; Morris, J.C.; et al. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer’s disease. *Alzheimers Res. Ther.* 2018, 10, 98. [CrossRef]

130. Wild, E.J.; Tabrizi, S.J. Huntington’s disease phenocopy syndromes. *Curr. Opin. Neurol.* 2007, 20, 681–687. [CrossRef]

131. Byrne, L.M.; Wild, E.J. Cerebrospinal Fluid Biomarkers for Huntington’s Disease. *J. Huntingt. Dis.* 2016, 5, 1–13. [CrossRef] [PubMed]

132. Constantinescu, R.; Rosengren, L.; Johnels, B.; Zetterberg, H.; Holmberg, B. Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson’s disease and atypical Parkinsonian disorders. *Parkinsonism Relat. Disord.* 2010, 16, 142–145. [CrossRef] [PubMed]

133. Herbert, M.K.; Aerts, M.B.; Beenes, M.; Norgren, N.; Esselink, R.A.; Bloem, B.R.; Kuiperij, H.B.; Verbeek, M.M. CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders. *Front. Neurol.* 2015, 6, 91. [CrossRef] [PubMed]

134. Abdo, W.F.; Bloem, B.R.; Van Geel, W.J.; Esselink, R.A.; Verbeek, M.M. CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson’s disease. *Neurobiol. Aging* 2007, 28, 742–747. [CrossRef] [PubMed]
135. Hall, S.; Ohrfelt, A.; Constantinou, R.; Andreasson, U.; Surova, Y.; Bostrom, F.; Nilsson, C.; Hakan, W.; Decraemer, H.; Nagga, K.; et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. *Arch. Neurol.* 2012, 69, 1445–1452. [CrossRef] [PubMed]

136. Magdalou, N.K.; Paterson, R.W.; Schott, J.M.; Fox, N.C.; Mummery, C.; Blennow, K.; Bhatia, K.; Morris, H.R.; Giunti, P.; Warner, T.T.; et al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. *J. Neurol. Neurosurg. Psychiatry* 2015, 86, 1240–1247. [CrossRef]

137. Marques, T.M.; van Rumund, A.; Oeckl, P.; Kuiperij, H.B.; Esselink, R.A.J.; Bloem, B.R.; Otto, M.; Verbeek, M.M. Serum NFL discriminates Parkinson disease from atypical parkinsonisms. *Neurology* 2019, 92, e1479–e1486. [CrossRef]

138. Sajjadi, S.A.; Acosta-Cabronero, J.; Patterson, K.; Diaz-de-Grenu, L.Z.; Williams, G.B.; Nestor, P.J. Diffusion tensor magnetic resonance imaging for single subject diagnosis in neurodegenerative diseases. *Brain* 2013, 136, 2253–2261. [CrossRef]

139. Surova, Y.; Szczepankiewicz, F.; Latt, J.; Nilsson, M.; Eriksson, B.; Leemans, A.; Hansson, O.; van Westen, D.; Nilsson, C. Assessment of global and regional diffusion changes along white matter tracts in parkinsonian disorders by MR tractography. *PLoS ONE* 2013, 8, e66022. [CrossRef]

140. Tsukamoto, K.; Matusue, E.; Kanasaki, Y.; Kakite, S.; Fujii, S.; Kaminou, T.; Ogawa, T. Significance of apparent diffusion coefficient measurement for the differential diagnosis of multiple system atrophy, progressive supranuclear palsy, and Parkinson’s disease: Evaluation by 3.0-T MR imaging. *Neuroradiology* 2012, 54, 947–955. [CrossRef]

141. Kuhle, J.; Barro, C.; Andreasson, U.; Derfuss, T.; Lindberg, R.; Sandelius, A.; Liman, V.; Norgren, N.; Blennow, K.; Zetterberg, H. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. *Clin. Chem. Lab. Med.* 2016, 54, 1655–1661. [CrossRef]

142. Johnson, W.; Onuma, O.; Owolabi, M.; Sachdev, S. Stroke: A global response is needed. *Bull. World Health Organ.* 2016, 94, 634. [CrossRef]

143. Collaborators, G.B.D.S. Global, regional, and national burden of stroke, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol.* 2019, 18, 439–458. [CrossRef]

144. Kaur, P.; Sharma, S. Recent Advances in Pathophysiology of Traumatic Brain Injury. *Curr. Neuropsychopharmacol.* 2018, 16, 1224–1238. [CrossRef]

145. Blennow, K.; Brody, D.L.; Kochanek, P.M.; Levin, H.; McKee, A.; Yaffe, K.; Zetterberg, H. Traumatic brain injuries. *Nat. Rev. Dis. Primers* 2016, 2, 16084. [CrossRef]

146. McCrory, P.; Meeuwisse, W.H.; Aubry, M.; Cantu, R.C.; Dvorak, J.; Echemendia, R.J.; Engebretsen, L.; Johnston, K.; Kean, J.; Kell, J.; et al. Consensus statement on concussion in sport: The 4th international conference on concussion in sport, Zurich, November 2012. *J. Athl. Train.* 2013, 48, 554–575. [CrossRef]

147. Teasdale, G. Assessment of head injuries. *Br. J. Anaesth.* 1976, 48, 761–766. [CrossRef]

148. Zetterberg, H.; Jonsson, M.; Rasulzada, A.; Popa, C.; Styrud, E.; Hietala, M.; Wallin, A.; Blennow, K. No neurochemical evidence for brain injury caused by heading in soccer. *Br. J. Sports Med.* 2007, 41, 574–577. [CrossRef]

149. Zetterberg, H.; Hietala, M.A.; Jonsson, M.; Andreassen, N.; Styrud, E.; Karlsson, I.; Edman, A.; Popa, C.; Rasulzada, A.; Wahlund, L.O.; et al. Neurochemical aftermath of amateur boxing. *Arch. Neurol.* 2006, 63, 1277–1280. [CrossRef]

150. Neselius, S.; Brisy, H.; Granholm, F.; Zetterberg, H.; Blennow, K. Monitoring concussion in a knocked-out boxer by CSF biomarker analysis. *Knee Surg. Sports Traumatol. Arthrosc.* 2015, 23, 2536–2539. [CrossRef]

151. Oliver, J.M.; Anzalone, A.J.; Stone, J.D.; Turner, S.M.; Blueitt, D.; Garrison, J.C.; Askow, A.T.; Luedke, J.A.; Jagim, A.R. Fluctuations in blood biomarkers of head trauma in NCAA football athletes over the course of a season. *J. Neurosurg.* 2018. [CrossRef]

152. Bernick, C.; Zetterberg, H.; Shan, G.; Banks, S.; Blennow, K. Longitudinal Performance of Plasma Neurofilament Light and Tau in Professional Fighters: The Professional Fighters Brain Health Study. *J. Neurotrauma* 2018, 35, 2521–2526. [CrossRef]

153. Iacono, D.; Shively, S.B.; Edlow, B.L.; Perl, D.P. Chronic Traumatic Encephalopathy: Known Causes, Unknown Effects. *Phys. Med. Rehabil. Clin. N. Am.* 2017, 28, 301–321. [CrossRef]
154. Korley, F.K.; Yue, J.K.; Wilson, D.H.; Hrusovsky, K.; Diaz-Arrastia, R.; Ferguson, A.R.; Yuh, E.L.; Mukherjee, P.; Wang, K.K.W.; Valadka, A.B.; et al. Performance Evaluation of a Multiplex Assay for Simultaneous Detection of Four Clinically Relevant Traumatic Brain Injury Biomarkers. *J. Neurotrauma* 2018. [CrossRef]

155. Young, G.B. Clinical practice. Neurologic prognosis after cardiac arrest. *N. Engl. J. Med.* 2009, 361, 605–611. [CrossRef]

156. Halaas, N.B.; Blennow, K.; Idland, A.V.; Wylle, T.B.; Raeder, J.; Frihagen, F.; Staff, A.C.; Zetterberg, H.; Watne, L.O. Neurofilament Light in Serum and Cerebrospinal Fluid of Hip Fracture Patients with Delirium. *Dement. Geriatr. Cogn. Disord.* 2018, 46, 346–357. [CrossRef]

157. Saller, T.; Petzold, A.; Zetterberg, H.; Kuhle, J.; Chappell, D.; von Dossow, V.; Klawitter, F.; Schurholz, T.; Hagl, C.; Reuter, D.A.; et al. A case series on the value of tau and neurofilament protein levels to predict and detect delirium in cardiac surgery patients. *Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub.* 2019, 163, 241–246. [CrossRef]

158. Szwed, K.; Slomka, A.; Pawliszak, W.; Szwed, M.; Anisimowicz, L.; Zekanowska, E.; Borkowska, A. Novel markers for predicting type 2 neurological complications of coronary artery bypass grafting. *Ann. Thorac. Surg.* 2019. [CrossRef]

159. Casey, C.P.; Lindroth, H.; Mohanty, R.; Farabakhsh, Z.; Ballweg, T.; Twadell, S.; Miller, S.; Krause, B.; Prabhakaran, V.; Blennow, K.; et al. Postoperative delirium is associated with increased plasma neurofilament light. *Brain* 2020, 143, 47–54. [CrossRef]

160. Mietani, K.; Sumitani, M.; Ogata, T.; Shimojo, N.; Inoue, R.; Abe, H.; Kawamura, G.; Yamada, Y. Dysfunction of the blood-brain barrier in postoperative delirium patients, referring to the axonal damage biomarker phosphorylated neurofilament heavy subunit. *PLoS ONE* 2019, 14, e0222721. [CrossRef]

161. Ehler, J.; Petzold, A.; Wittstock, M.; Kolbaske, S.; Gloger, M.; Henschel, J.; Heslegrave, A.; Zetterberg, H.; Lunn, M.P.; Rommer, P.S.; et al. The prognostic value of neurofilament levels in patients with sepsis-associated encephalopathy—A prospective, pilot observational study. *PLoS ONE* 2019, 14, e0211184. [CrossRef]

162. Steiner, I.; Gozzi, P.; Melamed, E. Progressive brain atrophy during normal aging in man: A quantitative computerized tomography study. *Isr. J. Med. Sci.* 1985, 21, 279–282.

163. Coffey, C.E.; Wilkinson, W.E.; Parashos, I.A.; Soady, S.A.; Sullivan, R.J.; Patterson, L.J.; Figiel, G.S.; Webb, M.C.; Spritzer, C.E.; Djang, W.T. Quantitative cerebral anatomy of the aging human brain: A cross-sectional study using magnetic resonance imaging. *Neurology* 1992, 42, 527–536. [CrossRef]

164. Cai, L.; Huang, J. Neurofilament light chain as a biological marker for multiple sclerosis: A meta-analysis study. *Neuropsychiatr. Dis. Treat.* 2018, 14, 2241–2254. [CrossRef]

165. Bridel, C.; van Wieringen, W.N.; Zetterberg, H.; Tijms, B.M.; Teunissen, C.E.; Alvarez-Cermeno, J.C.; Andreasson, U.; Axellsson, M.; Backstrom, D.C.; Bartos, A.; et al. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. *JAMA Neurol.* 2019. [CrossRef]

166. Kuhle, J.; Barro, C.; Disanto, G.; Mathias, A.; Soneson, C.; Bonnier, G.; Yaldizli, O.; Regeniter, A.; Derfuss, T.; Canales, M.; et al. Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity. *Mult. Scler.* 2016, 22, 1550–1559. [CrossRef]

167. Wilke, C.; Pujol-Calderon, E.; Barro, C.; Stransky, E.; Blennow, K.; Michalak, Z.; Deuschle, C.; Jeromin, A.; Zetterberg, H.; Schule, R.; et al. Correlations between serum and CSF pNfH levels in ALS, FTD and controls: A comparison of three analytical approaches. *Clin. Chem. Lab. Med.* 2019, 57, 1556–1564. [CrossRef]

168. Hakansson, I.; Tisell, A.; Cassel, P.; Blennow, K.; Zetterberg, H.; Lundberg, P.; Dahle, C.; Vrethem, M.; Ernerudh, J. Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis. *J. Neuroinflamm.* 2018, 15, 209. [CrossRef]

169. Norgren, N.; Karlsson, J.E.; Rosengren, L.; Stigbrand, T. Monoclonal antibodies selective for low molecular weight neurofilaments. *Hybrid. Hybridomics* 2002, 21, 53–59. [CrossRef]